| Phase 11 trial |
|
Phase 1
|
NCT05154604 |
Dec 2021 → Aug 2024 |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06434103 |
Oct 2024 |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Withdrawn
|
No outcome recorded
Stop: Business |
|
Phase 1/2
|
NCT05765032 |
Dec 2022 → Apr 2025 overdue |
neoplasm |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT06470672 |
Dec 2024 → Mar 2026 overdue |
hormone receptor-positive breast cancer |
Fudan University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06649331 |
Oct 2024 → Sep 2026 overdue |
triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06433609 |
Aug 2024 → Mar 2027 expected |
breast cancer |
Beijing GoBroad Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06480136 |
Jul 2024 → Jun 2027 expected |
non-small cell lung carcinoma |
Shanghai Pulmonary Hospital, Shanghai, China |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06465238 |
Jun 2024 → Jun 2026 overdue |
non-small cell lung carcinoma |
Henan Cancer Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06210438 |
Feb 2024 → Jun 2025 |
metastatic malignant neoplasm in the brain, triple-negative breast carcinoma |
Fudan University |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05924256 |
Jul 2023 → Dec 2026 expected |
salivary gland carcinoma |
Fudan University |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05594095 |
Dec 2022 → Dec 2025 overdue |
female breast carcinoma, hormone receptor-positive breast cancer |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05582499 |
Nov 2022 → Dec 2027 expected |
HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06394492 |
May 2024 → May 2026 overdue |
ovarian cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Comparator or background therapy1 trial |
|
Phase 1/2
|
NCT06474455 Background |
Jul 2024 → Jun 2029 expected |
cancer |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|